36
Participants
Start Date
August 31, 2008
Primary Completion Date
August 31, 2010
ABT-263
Single dose of the current ABT-263 formulation being assessed in ongoing Phase 1/2 studies vs. a single dose of one of the new ABT-263 formulation
ABT-263
Single dose of the current ABT-263 formulation being assessed in ongoing Phase 1/2a studies vs. a single dose of a new ABT-263 formulation followed by QD dosing with a new ABT-263 formulation for 7 days.
ABT-263
Single dose of the current ABT-263 formulation being assessed in ongoing Phase 1/2a studies vs. a single dose of a new ABT-263 formulation followed by QD dosing with a new ABT-263 formulation for 7 days.
Site Reference ID/Investigator# 16341, Bethesda
Site Reference ID/Investigator# 10282, Santa Monica
Site Reference ID/Investigator# 10281, Encinitas
Site Reference ID/Investigator# 9441, Lebanon
Site Reference ID/Investigator# 20041, Hackensack
Lead Sponsor
Collaborators (1)
Genentech, Inc.
INDUSTRY
Abbott
INDUSTRY